Impact of CYP2C9 polymorphisms on the vulnerability to pharmacokinetic drug-drug interactions during acenocoumarol treatment

By Gschwind Liliane   Rollason Victoria   Boehlen Françoise   Rebsamen Michela   Combescure Christophe   Grünenwald Michèle   Matthey Alain   Bonnabry Pascal   Dayer Pierre   Desmeules Jules Alexandre  

Pharmacogenomics, Vol. 14, Iss. 7, 2013-05 ,pp. : 745-753

Future Medicine

Access to resources Recommend Favorite

Association of Genetic Polymorphisms of CYP2C9 and VKORC1 with Bleeding Following Warfarin: A Case-Control Study

By  

Current Clinical Pharmacology, Vol. 11, Iss. 1, 2016-02 ,pp. : 62-68

Bentham Science Publishers

Access to resources Recommend Favorite

Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups

By Scott Stuart A   Khasawneh Rame   Peter Inga   Kornreich Ruth   Desnick Robert J  

Pharmacogenomics, Vol. 11, Iss. 6, 2010-06 ,pp. : 781-791

Future Medicine

Access to resources Recommend Favorite

Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians

By Borgiani Paola   Ciccacci Cinzia   Forte Vittorio   Romano Silvia   Federici Giorgio   Novelli Giuseppe  

Pharmacogenomics, Vol. 8, Iss. 11, 2007-11 ,pp. : 1545-1550

Future Medicine

Access to resources Recommend Favorite

A pharmacokinetic/pharmacodynamic analysis of a standard voriconazole regimen in different CYP2C19 genotypes by Monte Carlo simulation

By  

Die Pharmazie - An International Journal of Pharmaceutical Sciences, Vol. 70, Iss. 5, 2015-01 ,pp. : 306-309

Govi-Verlag

Access to resources Recommend Favorite